BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?

Scope 3 clauses, single-use plastic, water and energy intensity: the “green premium” has become the defining question for the CDMOs that built ...

July 13, 2026 | Analysis

APAC's Peptide-Capacity Gamble

For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first &mdash...

July 09, 2026 | Analysis

The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?

The requirement: a chain that cannot break Key figures −150°C or colder — the temperature floor for most cell and gene therapies; som...

July 06, 2026 | Analysis

Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck

THE GATE The choke point nobody puts on the slide Somewhere in the region this quarter, a cell-and-gene developer has everything the pitch deck promised....

July 03, 2026 | Analysis

The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026

For three years the biotechnology industry waited for a turn. The first half of 2026 delivered one — and then several more in quick succession. In si...

June 30, 2026 | Analysis

Security at What Cost? APAC and the Great Supply-Chain Reordering

For the better part of two decades, the global pharmaceutical supply chain ran on a simple, unsentimental bargain: make the chemistry where it is cheapest,...

June 24, 2026 | Analysis

Plastic, Steel and Software: APAC’s Next-Generation Bioprocessing Choice

When a biologics manufacturer in Bengaluru, Songdo or Singapore signs off on a new production suite today, the hardest question is rarely which molecule to...

June 23, 2026 | Analysis

After the Drug Substance, the Real Squeeze: APAC's Aseptic Fill-Finish Gap

For most of the last decade, the anxiety in Asia-Pacific biomanufacturing pointed upstream. The conversation was about bioreactor volume — how many t...

June 22, 2026 | Analysis

Good Enough and Cheap, or Prove It's Equivalent? Asia's Biosimilar Trust Gap

There is a number that captures Asia's biosimilar paradox in a single line. According to Samsung Bioepis's quarterly tracking of the United States market, ...

June 15, 2026 | Analysis

Scientific Infrastructure or Expensive Theatre? AI Discovery’s Reckoning in Asia

In October 2025, Eli Lilly announced it would build the most powerful supercomputer ever owned by a drug company. By February 2026, “LillyPod” ...

June 02, 2026 | Analysis

Can AI close the MSK inequality gap? Improving access to musculoskeletal care in the UK

Behind these statistics lies a deeper and more troubling social divide: that the greatest burden is carried by those in our most deprived communities and m...

April 14, 2026 | Opinion | By Peter Grinbergs, Chief Medical Officer and Co‑founder of EQL

From Staging to Survival: How AI-Driven Histological Analysis Is Solving Colorectal Cancer's Overtreatment Problem

The hidden cost of getting treatment decisions wrong Colorectal cancer (CRC) is one of the most prevalent and lethal cancers worldwide, ranking among the ...

April 02, 2026 | Expert Insight | By Dr. Torbjørn Furuseth, CEO and Co-Founder, DoMore Diagnostics

Thermo Fisher Scientific Launches Gibco CHOvantage GS Cell Line Development Kit To Accelerate Biologics Development

Gibco CHOvantage GS Cell Line Development Kit delivers high productivity, streamlined timelines and royalty-free, clinical-stage licensing options to suppo...

April 02, 2026 | News

APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage

APAC Biopharma in Review: What Truly Moved the Needle This Year Asia-Pacific (APAC) has cemented its status as a pivotal biopharmaceutical hub in 2025, ma...

December 15, 2025 | Report

Stay Connected